CYLD and neoplasm: In humans, recurrent loss of functional CYLD is reported in diverse cancers, including myeloma22, leukemia23,24, hepatocellular carcinoma25, neuroblastoma26, and pancreatic cancer27, consistent with its role as a tumor suppressor expressed ubiquitously in normal tissues.